Showing results (691-700 of 16,804) with videos related to
Sort By:
Pageof 1,681
British Journal of Haematology|April 7, 1999
Selective modulation of the cyclin B/CDK1 and cyclin D/CDK4 complexes during in vitro human megakaryocyte developmentA Bassini, S Pierpaoli, E Falcieri, et al.British Journal of Haematology|April 7, 1999
Three major G6PD-deficient polymorphic variants identified among the Mauritian populationR Kotea, J S Kaeda, S L Yan, et al.British Journal of Haematology|April 7, 1999
Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific ratesM Hickman, B Modell, P Greengross, et al.British Journal of Haematology|April 7, 1999
Up-regulation of adhesion and MHC molecules on splenic monocyte/macrophages in adult haemophagocytic syndromeA Keréveur, D McIlroy, A Samri, et al.British Journal of Haematology|April 7, 1999
Pregnancy-associated autoimmune neonatal thrombocytopenia: role of maternal HLA genotypeV Gandemer, C Kaplan, E Quelvennec, et al.British Journal of Haematology|April 7, 1999
A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresisJ L Hinks, P R Winship, M Makris, et al.British Journal of Haematology|October 9, 2003
Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemiasJan M Siehl, Eckhard Thiel, Karin Heufelder, et al.British Journal of Haematology|October 9, 2003
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemiaElaine Coustan-Smith, Raul C Ribeiro, Jeffrey E Rubnitz, et al.British Journal of Haematology|October 9, 2003
Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entitiesThomas Rasmussen, Kim Theilgaard-Mönch, Heidi R Hudlebusch, et al.British Journal of Haematology|October 9, 2003
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphomaGiovanni Martinelli, Daniele Laszlo, Francesco Bertolini, et al.Pageof 1,681